Yuhan Corporation (000100): Early-Stage Lazcluze European Commercialization — Milestone Deferral and Valuation Structure Review
Yuhan Corporation is experiencing short-term earnings volatility due to delayed milestone recognition timing as Lazcluze (lazertinib) enters its European commercialization phase. Q1 2026 consolidated revenue was 5,268억원 (≈$351.7M, YoY +7.2%) with operating profit of 88억원 (≈$5.9M, OPM 1.7%), and the Forward PER stands at 47.0x based on the current share price of 84,700원 (≈$56.5).
1. Company Overview and Core Business
Yuhan Corporation is a domestic pharmaceutical and biotech company founded in 1926, with ethical pharmaceuticals, active pharmaceutical ingredients (API), and health functional foods as its core businesses. On a consolidated basis in 2025, revenue reached KRW 2,186.6 billion (≈$1.5B) (YoY +5.7%) and operating income KRW 104.4 billion (≈$69.7M) (OPM 4.8%), maintaining financial stability with a debt-to-equity ratio of 36.4%. In Q1 2026, consolidated revenue was KRW 526.8 billion (≈$351.8M) (YoY +7.2%) and operating income was KRW 8.8 billion (≈$5.9M) (YoY +37.3%, OPM 1.7%), with the non-recognition of the Lazcluze European milestone (approximately KRW 44 billion (≈$29.4M)) serving as the direct cause of profitability falling short of market consensus. As of May 13, 2026, the current share price is KRW 84,700 (≈$56.5), with a market capitalization of approximately KRW 6.0 trillion (≈$4.0B).
📌 Q1 2026 OPM 1.7% — Temporary profitability constraint due to non-recognition of European milestone of approximately KRW 44 billion (≈$29.4M)
2. Core Product Competitiveness Analysis
The core pipeline is Lazcluze (lazertinib), a first-line non-small cell lung cancer (NSCLC) treatment co-developed with J&J, with the amivantamab (Rybrevant) combination therapy listed as a Category 1 preferred regimen in the US NCCN guidelines. In Q1 2026, based on J&J results, global sales of the Lazcluze-Rybrevant combination therapy reached $257 million (QoQ +19.0%)*1. Yuhan Chemical's API division is seeing expanded overseas order demand amid the China supply chain diversification trend, with a 300,000L capacity expansion currently underway on top of the existing 1,000,000L capacity base*2.
| Category | Details |
|---|---|
| Position | First-line NSCLC combination therapy; listed as NCCN Category 1 preferred regimen |
| Competitive Strengths | J&J global commercialization network; improved patient convenience from Rybrevant SC formulation transition |
| Competitive Weaknesses | Continued absence of European royalties; persistent low-margin structure at Q1 OPM of 1.7% |
3. Valuation Analysis
As of May 13, 2026, at a share price of KRW 84,700 (≈$56.5), the Trailing PER stands at 36.2x, a 22.3% premium over the sector average of 29.6x. The Forward PER has expanded to 47.0x vs. Trailing, as 2026 EPS is projected to fall below the 2025 level due to the base effect from non-recurring items (e.g., other non-operating income) that boosted 2025 earnings, along with the deferral of the Leclaza European milestone*3. The current 47.0x vs. the sector average Forward PER of 28.7x reflects a premium embedded in expectations for Leclaza royalty materialisation and earnings recovery. PBR is 2.80x and ROE is 7.8%.
📌 Forward PER 47.0x — expanded vs. Trailing 36.2x, simultaneously reflecting the 2026 EPS decline outlook and royalty recovery expectations
| Metric | Current | Sector Average | Interpretation |
|---|---|---|---|
| Trailing PER | 36.2x | 29.6x | 22.3% premium vs. sector |
| Forward PER | 47.0x | 28.7x | Expanded vs. Trailing — reflects 2026 EPS decline outlook |
| PBR | 2.80x | — | — |
| ROE | 7.8% | — | — |
| Operating Margin (2025A) | 4.8% | — | Highly volatile quarter-to-quarter depending on milestone recognition |
4. Risks and Monitoring Points
Further deferral of the Leclaza European milestone and a slowdown in royalty accumulation are the key variables driving near-term earnings volatility. Pipeline progress for YH35324 (entering Phase 2 trials for a novel allergy drug) and YH25724 (Phase 1 initiation planned for a MASH therapy), as well as the risk of delays in the Yuhan Chemical HC-dong capacity expansion (commercial launch target: H1 2028*2), could also affect medium-term earnings visibility.
- ⚠️ Risk of missing the 2026 operating profit consensus (KRW 127.5B–147.0B (≈$85.1M–$98.1M))*3 in the event of a further Leclaza European milestone deferral
- ⚠️ Slowdown in prescription growth if publication of overall survival (mOS) data for the Rybrevant combination regimen is delayed
- 📌 Timing of first Leclaza royalty receipt and quarterly J&J combination therapy revenue growth rate (whether QoQ +19% is sustained)*1
- 📌 Yuhan Chemical order announcement and HC-dong 300,000L capacity expansion progress (construction completion → H1 2028 commercial launch target)*2
5. Recent DART Disclosures
Two disclosures with high relevance to the report as of May 2026 have been selected.
| 날짜 | 공시명 | 요약 |
|---|---|---|
| 2026-05-14 | Other Management Matters (Voluntary Disclosure) | Yuhan Corporation submitted other management matters in the form of a voluntary disclosure. A voluntary disclosure is a method by which a company proactively discloses matters material to investment decisions; the specific contents require verification in the original DART filing. |
| 2026-05-11 | [Amendment] Decision on Paid-in Capital Increase (Material Matters of Subsidiary) | An amendment was filed correcting the previously disclosed decision on paid-in capital increase by a subsidiary. The correction is presumed to reflect changes to the capital-raising details of subsidiaries such as Yuhan Chemical; the precise amended items can be confirmed in the original filing. |
For Yuhan Corporation, the timing of Lazcluze European royalty recognition and the pace of earnings growth are the key variables for valuation re-rating. Key indicators to monitor from Q2 2026 onward include milestone and royalty receipt status, as well as J&J's quarterly combination therapy revenue growth rate.
📎 출처 및 추정 근거
- *1 Based on J&J's Q1 2026 earnings release (April 2026), global revenue from the Lazcluze · Rybrevant combination therapy was $257 million (YoY +82%, QoQ +19%). Source: Kiwoom Securities Research (2026-04-20) and Kyobo Securities Research (2026-05-07), commonly cited.
- *2 Based on Yuhan Chemical's existing capacity of 1 million L, construction of the HC building for a 300,000 L capacity expansion commenced in March 2026, targeting commercial production in H1 2028. Source: Kyobo Securities Research (2026-05-07). Target figures are based on official company guidance and actual timelines are subject to change.
- *3 Basis for 2026 EPS decline forecast: Forward PER of 47.0x based on input data (implied 2026F EPS of approximately 1,802원 (≈$1.2) back-calculated from current share price of 84,700원 (≈$56.5)) exceeds Trailing PER of 36.2x (implied EPS of approximately 2,340원 (≈$1.6)). Broker estimates diverge: Kiwoom 2026F EPS 1,852원 (≈$1.2) (2026-04-20), Kyobo 2026F EPS 2,471원 (≈$1.6) (2026-05-07). 2026 operating profit consensus range: Kiwoom 1,275억원 (≈$85.1M) · Kyobo 1,470억원 (≈$98.1M).
- *4 USD equivalents (≈$) are approximate, calculated at 1 USD = 1,498 KRW (as of 2026-05-16, source: Yahoo Finance via TradeAlert).
본 보고서는 정보 제공 목적이며 투자 권유가 아닙니다. 투자 결정은 본인 책임입니다.
댓글 없음:
댓글 쓰기